Prognostic role of masked and white-coat hypertension: 10-Year mortality in treated elderly hypertensives

Journal of Human Hypertension

Volumn 33, Issue 10, 2019, Pages 741-747

  Spannella, Francesco ^a,b   Filipponi, Andrea ^a,b   Giulietti, Federico ^a,b   Balietti, Paolo ^a,b   Bernardi, Beatrice ^a,b   Rosettani, Giulia ^a,b   Sarzani, Riccardo ^a,b  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; CAUSE OF DEATH; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASKED UNCONTROLLED HYPERTENSION; MORTALITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; SUSTAINED CONTROLLED HYPERTENSION; SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION; WHITE COAT UNCONTROLLED HYPERTENSION; BLOOD PRESSURE; DRUG EFFECT; MASKED HYPERTENSION; PATHOPHYSIOLOGY; RISK ASSESSMENT; TIME FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; MALE; MASKED HYPERTENSION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WHITE COAT HYPERTENSION;

EID: 85058026011     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/s41371-018-0140-4     Document Type: Article

References (37)

1. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8:13–28.
2. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52:818–27.
3. Tocci G, Presta V, Figliuzzi I, Attalla El Halabieh N, Battistoni A, Coluccia R, et al. Prevalence and clinical outcomes of white-coat and masked hypertension: analysis of a large ambulatory blood pressure database. J Clin Hypertens. 2018;20:297–305.
4. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593–9.
5. Hänninen MR, Niiranen TJ, Puukka PJ, Kesäniemi YA, Kähönen M, Jula AM. Target organ damage and masked hypertension in the general population: the Finn-Home study. J Hypertens. 2013;31:1136–43.
6. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043–50.
7. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508–15.
8. Balietti P, Spannella F, Giulietti F, Rosettani G, Bernardi B, Cocci G, et al. Ten-year changes in ambulatory blood pressure: the prognostic value of ambulatory pulse pressure. J Clin Hypertens (Greenwich). 2018;20:1230–7.
9. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.
10. O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821–48.
11. Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378:1509–20.
12. Mancia G. White-coat hypertension: growing evidence in favour of its adverse prognostic significance. J Hypertens. 2017;35:710–2.
13. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation—United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1227–32.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
15. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061–8.
16. Spannella F, Giulietti F, Fedecostante M, Ricci M, Balietti P, Cocci G, et al. Interarm blood pressure differences predict target organ damage in type 2 diabetes. J Clin Hypertens. 2017;19:472–8.
17. Omboni S, Palatini P, Parati G. Standards for ambulatory blood pressure monitoring clinical reporting in daily practice: recommendations from the Italian Society of Hypertension. Blood Pressure Monit. 2015;20:241–4.
18. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;00:1–98.
19. Fedecostante M, Spannella F, Giulietti F, Espinosa E, Dessì-Fulgheri P, Sarzani R. Associations between body mass index, ambulatory blood pressure findings, and changes in cardiac structure: relevance of pulse and nighttime pressures. J Clin Hypertens. 2015;17:147–53.
20. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.
21. Maselli M, Giantin V, Franchin A, Zanatta F, Sarti S, Corradin ML. Detection of blood pressure increments in active elderly individuals: the role of ambulatory blood pressure monitoring. Nutr Metab Cardiovasc Dis. 2014;24:914–20.
22. Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015;66:2159–69.
23. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25:2193–8.
24. Fujiwara T, Yano Y, Hoshide S, Kanegae H, Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese general practice population. JAMA Cardiol. 2018;3:583–90.
25. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–324.
26. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol. 2001;38:238–45.
27. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291:1342–9.
28. Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, et al. Prognosis of white-coat and masked hypertension: International Database of Home blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014;63:675–82.
29. Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677–88.
30. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385–92.
31. Cuspidi C, Facchetti R, Bombelli M, Sala C, Tadic M, Grassi G. Risk of new-onset metabolic syndrome associated with white-coat and masked hypertension: data from a general population. J Hypertens. 2018;36:1833–183931.
32. Mancia G. Clinical significance of white-coat hypertension. J Hypertens. 2016;34:623–6.
33. Mancia G, Bombelli M, Cuspidi C, Facchetti R, Grassi G. Cardiovascular risk associated with white-coat hypertension: pro side of the argument. Hypertension. 2017;70:668–75.
34. Franklin SS, Thijs L, Asayama K, Li Y, Hansen TW, Boggia J, et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68:2033–43.
35. Ben-Dov IZ, Kark JD, Mekler J, Shaked E, Bursztyn M. The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. J Hypertens. 2008;26:699–705.
36. Franklin SS, Thijs L, Hansen TW, Li Y, Boggia J, Kikuya M, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59:564–71.
37. Harrell FE,Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69:1071–77.